St. Marianna University School of Medicine

www.marianna-u.ac.jp/
Kawasaki, Japan

St. Marianna University School of Medicine is a private university in Miyamae-ku, Kawasaki, Kanagawa Prefecture, Japan. Established in 1971, it is a medical school affiliated with the Roman Catholic Church. In additional to medical studies, the school offers a degree in comparative religious studies. The school is also the first in Asia to be approved as a medical center for the FIFA world soccer association, and is the medical provider for the Japan national football team. Wikipedia.


Time filter

Source Type

Patent
St. Marianna University School of Medicine and Hamamatsu Photonics K K | Date: 2017-01-04

A concentration measurement apparatus 1 measures a temporal relative change amount (cHb, O_(2)Hb) of either or both of total hemoglobin concentration and oxygenated hemoglobin concentration in the head that vary due to repetition of chest compression, and includes a light incidence section 21 making measurement light incident on the head, a light detection section 22 detecting the measurement light propagated through the interior of the head and generating a detection signal in accordance with the intensity of the measurement light, and a CPU 14 determining, based on the detection signal, the relative change amount (cHb, O_(2)Hb) and performing a filtering process of removing frequency components less than a predetermined frequency from frequency components contained in the relative change amount (cHb, O_(2)Hb). A concentration measurement apparatus and a concentration measurement method that enable objective judgment of whether or not chest compression is being performed appropriately are thereby realized.


Patent
Kitazato BioPharma Co. and St. Marianna University School of Medicine | Date: 2017-02-27

A collected living tissue cryopreserving appliance is composed of a collected tissue accommodating container, a heat-sealable accommodating bag for accommodating the collected tissue accommodating container therein, and a container holding member for holding the collected tissue accommodating container accommodated inside the accommodating bag. The collected tissue accommodating container is composed of a bottomed cylindrical container body and a lid member mountable on the container body in an airtight state. The lid member has a tissue piece placing member and a sealing member, formed on an inner surface of a lid body part, for sealing an open portion of the transparent container body.


Patent
St. Marianna University School of Medicine and Kyowa Hakko Kirin Co. | Date: 2017-03-31

The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.


Patent
Kitazato BioPharma Co. and St. Marianna University School of Medicine | Date: 2017-07-26

A collected living tissue cryopreserving appliance (1) is composed of a collected tissue accommodating container (2), a heat-sealable accommodating bag (5) for accommodating the collected tissue accommodating container (2) therein, and a container holding member (6) for holding the collected tissue accommodating container (2) accommodated inside the accommodating bag (5). The collected tissue accommodating container is composed of a bottomed cylindrical container body (3) and a lid member (4) mountable on the container body in an airtight state. The lid member (4) has a tissue piece placing member (41) and a sealing member (48), formed on an inner surface of a lid body part (42), for sealing an open portion of the transparent container body (3).


Patent
St. Marianna University School of Medicine and Hamamatsu Photonics K K | Date: 2014-02-26

A concentration measurement apparatus 1 measures a temporal relative change amount (cHb, O_(2)Hb) of either or both of total hemoglobin concentration and oxygenated hemoglobin concentration in the head that vary due to repetition of chest compression, and includes a light incidence section 21 making measurement light incident on the head, a light detection section 22 detecting the measurement light propagated through the interior of the head and generating a detection signal in accordance with the intensity of the measurement light, and a CPU 14 determining, based on the detection signal, the relative change amount (cHb, O_(2)Hb) and performing a filtering process of removing frequency components less than a predetermined frequency from frequency components contained in the relative change amount (cHb, O_(2)Hb). A concentration measurement apparatus and a concentration measurement method that enable objective judgment of whether or not chest compression is being performed appropriately are thereby realized.


Patent
Hitachi Ltd., St. Marianna University School of Medicine and National Institute Of Agrobiological Science | Date: 2015-03-04

The present invention can provide a controlled drug release carrier formed by using a silk fibroin porous material, which has high drug controlled release rate, controllability of the drug controlled release speed, high strength, easy handleability, skin care properties from high biocompatibility, high water retentivity, and capability of efficiently retaining a drug.


Patent
St. Marianna University School of Medicine and Terumo Kabushiki Kaisha | Date: 2016-05-11

A bone cement injection puncture needle (10a) comprises: an outer needle (12a) of hollow constitution having a proximal end side hole (24a) formed in a side surface near a proximal end portion thereof; an outer needle hub (14a) fixed to the proximal end portion of the outer needle (12a) and having a first port (32) held in fluid communication with a proximal end opening of the outer needle (12a); an inner needle (16) having a needle point on a distal end thereof and which is insertable in the outer needle (12a) and the first port (32); an inner needle hub (18a) fixed to a proximal end portion of the inner needle (16) and which is removably mountable on the outer needle hub (14a); an inner tube (17) insertable in the outer needle (12a) and the first port (32); and an inner tube hub (19) fixed to a proximal end portion of the inner tube (17) and which is removably mountable on the outer needle hub (14a), the inner tube hub (19) having a second port (56) held in fluid communication with a proximal end opening of the inner tube (17). When the inner tube (17) is inserted in the outer needle (12a), a depressurization passage (75), which opens at a most distal end portion of the outer needle (12a) and provides fluid communication with the proximal end side hole (24a), is formed between the outer needle (12a) and the inner tube (17).


Boku N.,St. Marianna University School of Medicine
Gastric Cancer | Year: 2014

Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis and poor outcomes of several types of cancer, including advanced gastric and gastroesophageal junction cancer. Molecular-targeted drugs, such as trastuzumab, which prolong overall survival and progression-free survival in HER2-positive breast cancer, may also be beneficial in patients with HER2-positive gastric cancer. Several studies have examined this possibility, such as the Trastuzumab for Gastric Cancer trial. In this context, the first part of this review provides an update on our knowledge of HER2 in breast and gastric cancer, including the detection and prognostic relevance of HER2 in gastric cancer. The second part of the review discusses the results of pivotal clinical trials that examined the potential for using trastuzumab to treat this disease. This section also summarizes the trials that have been conducted or that are underway to determine the optimal uses of trastuzumab in gastric cancer, including its use as monotherapy and continuation beyond disease progression. The final section discusses the future prospects of other anti-HER2 drugs, including lapatinib, trastuzumab emtansine, and pertuzumab, for the treatment of HER2-positive gastric cancer. The introduction of trastuzumab led to the establishment of a new disease entity, "HER2-positive gastric cancer," similar to HER2-positive breast cancer. It is expected that more anti-HER2 drugs will be developed and introduced into clinical practice to treat HER2-positive cancers, including gastric cancer. © 2013 The Author(s).


A device for treating carbon monoxide poisoning includes a light emitter that emits light having a wavelength in the range of from 600 to 750 nm. An upper clothing of the present invention emits light having a wavelength in the range of from 600 to 750 nm on the inside of a front body and/or a back body. A catheter of the present invention includes a catheter body that has a distal end portion formed of a light-transmissive material and that includes a plurality of lumens; a light emitter that emits light having a wavelength in the range of from 600 to 750 nm to allow the light to exit through a first lumen from the distal end portion of the catheter body; a balloon that is disposed around a circumferential surface of the distal end portion, that is in communication with a second lumen, and that guides the distal end portion to downstream blood flow in an inflated state; and a pressure sensor that is disposed at the distal end of the distal end portion and that is connected to a cable inserted through a third lumen.


Patent
St. Marianna University School of Medicine and Kyowa Hakko Kirin Co. | Date: 2015-05-13

The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1(HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.

Loading St. Marianna University School of Medicine collaborators
Loading St. Marianna University School of Medicine collaborators